Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Martin Fan maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Outperform and raises the price target from $23 to $40.
Wedbush analyst Martin Fan maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Outperform and raises the price target from $23 to $40.